Obesity – Page 7

Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks

7 months ago talkbio0Tagged Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Nordisk, Obesity, triple agonist, UBT251, United Laboratories International Holdings Limited

Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

7 months ago talkbio0Tagged Cell Differentiation process, competition, Glucagon-Like Peptide 1, Obesity, weight loss market

GLP-1 drugs, weight loss market, differentiation, competition, obesity treatment

Roche expands obesity pipeline, paying Zealand Pharma $1.65B upfront to codevelop amylin asset

7 months ago talkbio0Tagged competitive weight loss medication, drug pipeline, expansion, Obesity, Partnership, Roche 's

This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.

Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate

7 months ago talkbio0Tagged CordenPharma, GLP-1/GIP, Manufacturing, Obesity, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

7 months ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations